Skip to Content

'
Nizar M. Tannir, MD, FACP

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
Deputy Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

There has been significant progress made in the treatment of clear-cell renal cell carcinoma (RCC), with several targeted agents now approved.  However, the vast majority of patients develop progressive disease within a year. Despite the clinical efficacy of targeted agents, significant toxicity hampers patient benefit, and <30% of patients with metastatic RCC survive >five years. Furthermore, insight into the biology of non-clear cell RCC subtypes has lagged behind clear-cell RCC, with few relevant targets identified. Currently, there is no established effective therapy for this diverse group of non-clear cell RCC subtypes. Therapeutic strategies using immune checkpoint antibodies are revolutionizing the treatment of many cancers including RCC, but at best 50% of patients with metastatic RCC respond to the combination of anti-PD-1 and anti-CTLA-4 antibodies. The long-term follow-up of patients with metastatic RCC treated with these novel immune approaches will be awaited to assess their curative potential. 

My research focus in RCC is in the following areas:

  • Clinical and molecular characterization of non-clear cell RCC subtypes, particularly translocation RCC and renal medullary carcinoma
  • Design and conduct of informative, biology-driven clinical trials for clear-cell and non-clear cell RCC
  • Identification of circulating and tissue-based biomarkers of response to targeted agents and immune checkpoint antibodies in patients with clear-cell and non-clear cell RCC

The projects outlined above are currently being carried out in the context of several investigator-initiated, approved, and funded clinical and laboratory trials in metastatic clear-cell and non-clear cell RCC, on which I serve as principal investigator.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3470
Fax: 713-745-0422

Education & Training

Degree-Granting Education

1979 American University of Beirut, Beirut, Lebanon, MD, Medicine
1975 American University of Beirut, Beirut, Lebanon, BS, Biology/Chemistry

Postgraduate Training

8/2000-11/2000 Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1985-6/1986 Clinical Fellowship, Hematology, University of Medicine and Dentistry of New Jersey, Newark, NJ
7/1981-6/1984 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Hospital and Tumor Institute, Houston, TX

Board Certifications

11/2000 American Board of Internal Medicine/Hematology
11/2000 American Board Internal Medicine/Medical Oncology
1/1987 American Board Internal Medicine/Medical Oncology
1/1986 American Board of Internal Medicine/Hematology
1/1985 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2014
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 3/2001-8/2007
Visiting Scientist, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 5/2000-7/2000

Administrative Appointments/Responsibilities

Director, Genitourinary Medical Oncology Clinic, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present
Director, Kentucky Cancer Clinic, Hazard, KY, 11/1997-12/1999
Voluntary Faculty, University of Kentucky, Lexington, KY, 11/1986-12/1999

Other Appointments/Responsibilities

Private Practice; Hematology Oncology, Appalachian Regional Medical Center, Hazard, KY, 11/1986-12/1999

Institutional Committee Activities

Chair, Division of Cancer Medicine Clinical Competency Committee, 1/2014-present
Member, Division of Cancer Medicine Clinical Competency Committee, 1/2013-12/2013
Member, Clinical Research and Patient Care Committee, 9/2011-present
Member, Division of Cancer Medicine Hematology/Oncology Fellowship Program Steering Committee, 9/2009-present

Honors and Awards

2014 Melvin L. Samuels Award for Excellence in Patient Care, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine Faculty Recognition and Awards
2014 Waun Ki Hong Leadership in Education, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2013 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2013 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2013 Gerald P. Bodey Award for Excellence in Education, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine Faculty Recognition and Awards
2012 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2012 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2012 Top Doctor 2012, US News and World Report
2011 Top Doctor 2011, US News and World Report
2010 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2010 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2008 America's Top Oncologist, Guide to America's Top Oncologists
2008 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2008 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2008 Vicente Valero LBJ Clinician-Educator of the Year, LBJ Hospital / The University of Texas MD Anderson Cancer Center
2001 Benefactors Award, Governor of Kentucky

Selected Publications

Peer-Reviewed Original Research Articles

1. Land JD, Chen AH, Atkinson BJ, Cauley DH, Tannir NM. Proteinuria with first-line therapy of metastatic renal cell cancer. J Oncol Pharm Pract 22(2):235-41, 4/2016. e-Pub 12/9/2014. PMID: 25505255.
2. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 6/2015. e-Pub 10/24/2014. PMID: 25465491.
3. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep 27(2):18-20, 3/1/2015. PMCID: PMC4477704.
4. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Tannir NM. Neuroendocrine Tumors of the Kidney: A Single Institution Experience. Clin Genitour Cancer 12(6):422-27, 12/2014. NIHMSID: NIHMSNIHMS618553.
5. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 32(6):1246-57, 12/2014. e-Pub 8/2014. PMID: 25142258.
6. Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: A single institution experience. Clin Genitourin Cancer 12(5):348-53, 10/2014. e-Pub 1/2014. PMCID: PMC4160412.
7. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Patel S, Tannir NM. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol. e-Pub 9/2014. PMID: 25222071.
8. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Compérat E, Couturier J, Molinié V, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM. Next generation sequencing of translocation renal cell carcinomas reveals novel RNA splicing partners and frequent mutations of chromatin remodeling genes. Clin Cancer Res 20(15):4129-40, 8/2014. e-Pub 6/2014. PMCID: PMC4167829.
9. Tu SM, Bilen MA, Tannir NM. The scientific method: pillar and pitfall of cancer research. Cancer Med 3(4):1035-7, 8/2014. e-Pub 4/2014. PMCID: PMC4303171.
10. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 113(3):376-82, 3/2014. e-Pub 12/2013. PMCID: PMC3944913.
11. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 10/2013. e-Pub 6/2013. PMCID: PMC3882156.
12. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 36(5):450-4, 10/2013. e-Pub 6/2012. PMCID: PMC3882166.
13. Conter HJ, Lim ZD, Ng CS, Millikan RE, Tannir NM. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: A case report of a 55-year-old man with a 10-year complete remission. Clin Genitourin Cancer 11(3):370-3, 9/2013. e-Pub 5/2013. PMID: 23665133.
14. Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 19(17):4673-4684, 9/2013. e-Pub 7/2013. PMCID: PMC3882157.
15. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol 52(7):856-61, 7/2013. e-Pub 5/2013. PMID: 23675612.
16. Lim ZD, Mahajan A, Weinberg J, Tannir NM. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol 36(3):258-60, 6/2013. e-Pub 3/20/2012. PMID: 22441343.
17. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 12/2012. e-Pub 6/2012. PMCID: PMC3882163.
18. Richey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic extraosseous Ewing's sarcoma (EES)/Primitive Neuroectodermal Tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy. Clin Genitourin Cancer 10(3):210-2, 9/2012. e-Pub 4/2012. NIHMSID: NIHMSNIHMS611584.
19. Matrana MR, Ng C, Rao P, Lim ZD, Tannir NM. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer 9(2):137-9, 12/2011. e-Pub 8/10/2011. PMID: 21831725.
20. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47(18):2706-14, 12/2011. e-Pub 11/2011. PMID: 22078932.
21. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol 6(3):189-98, 8/2011. PMID: 21827388.
22. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions. Hematol Oncol Clin North Am 25(4):853-869, 8/2011. PMID: 21763971.
23. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22(5):1048-53, 5/2011. e-Pub 11/29/2010. PMID: 21115604.
24. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 29(8):e203-5, 3/10/2011. e-Pub 12/20/2010. PMID: 21172884.
25. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. BJU Int 107(5):741-7, 3/2011. e-Pub 9/2010. PMID: 21355978.
26. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439-44, 2/2011. e-Pub 12/17/2010. PMID: 21167518.
27. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1):10-5, 1/2011. e-Pub 10/16/2010. PMID: 20952123.
28. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 10(12):1883-9, 12/2010. PMID: 21110755.
29. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 116(22):5219-25, 11/15/2010. e-Pub 2010. PMID: 20665500.
30. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol 5(2):113-8, 6/2010. e-Pub 7/14/2010. PMID: 20625844.
31. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. Am J Roentgenol 194(1):166-71, 1/2010. PMID: 20028919.
32. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/2010. e-Pub 10/2009. PMID: 19862815.
33. Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in metastatic renal cell cancer: association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 10/2009. e-Pub 6/18/2009. PMCID: PMC4542573.
34. Jonasch E, Wood CG, Matin SF, Tu S-M, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008.
35. Rodney A, Gombos D, Fuller G, Pagliaro LC, Tannir N. Choroidal and conjunctival metastases from renal cell carcinoma. Am J Clin Oncol 32(4):448-9, 8/2009. PMID: 19657240.
36. Rodney AJ, Gombos DS, Pagliaro LC, Tannir NM. Ischemic optic neuropathy associated with low dose interferon alfa: Report of two cases. Am J Clin Oncol 32(1):86-87, 2/2009. PMCID: PMC4121058.
37. Dubauskas Z, Kunishige J, Prieto VG, Kantrow SM, Jonasch E, Hwy P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20-3, 1/2009. PMID: 19213663.
38. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro, L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine in metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 9/2008. NIHMSID: NIHMSNIHMS615126.
39. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: A case report. Clin Genitourin Cancer 6(2):122-123, 9/2008. PMID: 18824436.
40. Jonasch E, Wood C, Tamboli P. Pagliaro LC, Tu SM, Kim J, Sirvastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, 4/2008. PMID: 18362942.
41. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 14(5):315-9, Sep-Oct, 2008. PMID: 18836336.
42. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-702, 4/2007. PMID: 17427204.
43. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 11/2006. PMID: 17029276.
44. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 2006. PMID: 16795067.
Other Articles
1. Mehta KU, Gascon P, Tannir N, Lombardo J, Robboy SJ. Impaired bone marrow in AIDS. N J Med 86(8):623-627, 8/1989. PMID: 2685666.

Abstracts

1. Agulnik M, Tannir NM, Pressey JG, Gounder MM, Cote GM, Roche M, Doleman S, Blakemore SJ, Clawson A, Daigle S, Tang J, Ho PTC, Demetri GD. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. J Clin Oncol 34(Suppl) (#TPS11071), 2016.
2. Naing A, Papadopoulos KP, Infante JR, Wong DJL, Autio KA, Ott PA, Falchook GS, Patel MR, Pant S, Patniak A, Mumm JB, Whiteside M, Chan IH, Bendell JC, Bauer TM, Janku F, Colen RR, Tannir NM, Vlasselaer PV, Oft M. Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1. J Clin Oncol 34(Suppl) (#3018), 2016.
3. Malour GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Mouawad R, Pal SK, Su X, Sircar K, Tamboli P, JOnasch E, Tannir NM, Wood CG, Karam JA. Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations. J Clin Oncol 34(suppl 2S) (#537), 2016.
4. Malour G, Su X, Zhang J, Ho TH, Lu Y, Raynal NJM, Karam JA, Tamboli P, Allanick F, Mouawad R. Khayat D, Wood CG, Jelinek J, Tannir NM. DNA methylation profiling of renal cell carcinomas subtypes to identify epi-clusters linked to cell ontogeny. J Clin Oncol 34(Suppl) (#4512), 2016.
5. Malouf GG, Su X, Zhang J, Ho TH, Lu Y, Raynal NJM, Karam JA, Tamboli P, Allanick F, Mouawad R, Khayat D, Wood CG, Jelinek J, Tannir NM. DNA methylation signature to define cell ontogeny of renal cell carcinomas. J Clin Oncol 34(suppl 2S) (#536), 2016.
6. Kawakami F, Sircar K, Rodriguez-Canales J, Tamboli P, Tannir NM, Jonasch E, Wistuba I, Wood CG, Karam JA. Expression of PD-1 and PD-L1 in patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). J Clin Oncol 34(suppl 2S) (#582), 2016.
7. Shah AY, Karam JA, Malouf G, Pao P, Lim Z, Jonasch E, Xiao L, Gao JJ, Vaishampayan U, Heng DY, Plimack E, Guancial E, Fung C, Lowas S, Tamboli P, Sircar K, Matin S, Rathmell K, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients. J Clin Oncol 34(Suppl) (#e16111), 2016.
8. Gao JJ, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir NM. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. J Clin Oncol 34(suppl 2S) (#571), 2016.
9. Gao JJ, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir NM. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. J Clin Oncol 34(Suppl) (#4566), 2016.
10. Choueiri TK, Poweles T, Escudier BJ, Tannir NM, Mainwaring P, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Aftab DT, Hessel C, Scheffold C, Schwab G, Pal SK, Hutson TE, Motzer RJ. Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 34(Suppl) (#4506), 2016.
11. Meric-Bernstam F, Tannir NM, Mier JW, DeMichele A, Telli ML, Fan AC, Munster PN, Carvajal RD, Orford KW, Bennett MK, Iliopoulos O, Owonikoko TK, Patel MR, McKaye R, Infante JR, Voss MH, Harding JJ. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). J Clin Oncol 34(Suppl) (#4568), 2016.
12. Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Prognostic and predictive plasma cytokines and angiogenic factors (CAF) in patients (pts) with advanced non-clear cell renal cell carcinoma treated with first-line sunitinib or everolimus: Results from the ESPN trial. J Clin Oncol 34(Suppl) (#e16112), 2016.
13. Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grunwald V, Heng DYC, Hutson T, Melichar B, Nosov D, Rini BI, Salman P, Sternberg CN, Szczylik C, Wolter P, Arroyo AM, Mangeshkar M, Agarwal N, Choueiri TK. Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 34(suppl 2S) (#499), 2016.
14. Jonasch E, Hoang A, Sun M, Zhou L, Ding Z, Zhang X, Bai S, Tannir NM, Liu X. Sunitinib to upregulate IFNg-STAT1 signaling and to increase indoleamine 2,3-dioxygenase (IDO) expression in renal cell carcinoma (RCC). J Clin Oncol 34(suppl 2S) (#614), 2016.
15. Thomas AZ, Abidi M, Slack R, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The role of metastasectomy in patients with renal cell carcinoma with sarcomatoid dedifferentiation: A matched controlled analysis. J Clin Oncol 34(suppl 2S) (#565), 2016.
16. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in renal cell carcinoma etiology. Cancer Res 75(suppl 15) (#836), 8/2015.
17. Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin S, Karam JA. MicroRNA expression links obesity and recurrence in renal cell carcinoma. Cancer Res 75(suppl 15) (#3999), 8/2015.
18. Ochoa A, Zhang J, Choi W, Malouf G, Thompson E, Weinstein J, Tannir NM, Dinney C, McConkey D, Su X. The Long non-coding RNA SNHG18 promotes PPARy function and "luminal" gene expression in muscle-invasive bladder cancer. J Urol 193(4):e923 (#MP72-06), 4/2015.
19. Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. J Clin Oncol 33(suppl 7) (#419), 2/2015.
20. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Bai S, German P, Zhang X, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Tannir NM, Sircar K. Anti-angiogenic therapy induces T-lymphocyte infiltration associated with poor survival in metastatic renal cell carcinoma patients. Eur J Cancer 20(suppl 6):172 (#530), 11/2014.
21. Melkonian S, Daniel CR, Hildebrandt M, Tannir NM, Ye Y, Chow WH, Wood C, Wu X. Established genetic variants and dietary patterns jointly impact risk of renal cell carcinoma in non-Hispanic whites. Cancer Res 74(Suppl 19) (#1262), 10/2014.
22. Sun M, Monzon FA, Zhou L, Liu X, Ding Z, Zhang X, Bai S, German P, Kalra S, Park, IY, Dere R, Berry T, Tong X, Walker C, Tannir NM, Matin S, Fuller G, Mccutcheon IE, Liu XD. Identification of molecular drivers of human hemangioblastoma. Cancer Res 74(suppl 19) (#2224), 10/2014.
23. Malouf GG, Zhang J, Tannir N, Thompson EJ, Khayat D,Spano J-P, Su X. Long non-coding RNA subtype classification of clear-cell renal cell carcinoma. Cancer Res 74(Suppl 19) (#3559), 10/2014.
24. Wang X, Melkonian S, Gu J, Chang D, Tannir NM, Wood C, Wu X. Mitochondrial DNA copy number in peripheral blood and the risk of clear-cell renal cell carcinoma: Effect of age, gender, smoking, and history of hypertension. Cancer Res 74(suppl 19) (#4320), 10/2014.
25. Zhou L, Liu X, Sun M, Tannir NM, Laird D, Liu XD. The mechanisms of anti-VEGF therapy resistance in renal cell carcinoma. Cancer Res 74(suppl 19) (#687), 10/2014.
26. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Hoang A, Efstathiou E, Liu XD, BAi S, German P, Zhou L, Jonasch D, Zhang X, Conti CJ, Tannir NM, Eissa NT, Mills GB, Walker CL. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene 74(suppl 19) (#312), 7/2014.
27. Kim DY, Wood CG, Busch A, Qiao W, Tamboli P, Jonasch E, Tannir NM, Matin SF, Karam JA. Survival and prognostic variables predicting survival in T4 renal cell carcinoma. J Urol 191(4):e386-7 (#MP36-20), 4/2014.
28. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Cron PG, Tannir NM, Jonasch E. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. J Clin Oncol 32(suppl 4) (#528), 2/2014.
29. Kalra S, Atckinson BJ, Matrana MR, Matin SF, Wood CG Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir, NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. J Clin Oncol 32(suppl 4) (#527), 2/2014.
30. Malouf G, Zhang J, Tannir NM, Erika Thompson E, S J-P, Khayat D, Su X. Association of CpG island methylator phenotype with clear-cell renal cell carcinoma aggressiveness. J Clin Oncol 32(5s):suppl; abstr 4574, 2014.
31. Tannir NM, Jonasch E, Altinmakas Emre, Ng CS, Qiao W, Tamboli P, Rao P, McDermott DF, Wood CG, Choueiri T. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. J Clin Oncol 32(5s):suppl (#4505), 2014.
32. Gao J, Yao H, Su X, Rao P, Sharma P, Karam JA, Wood CG, Tannir NM. Molecular characterization of renal medullary carcinoma (RMC). J Clin Oncol 32(5s):suppl; abstr 4586, 2014.
33. Nieto Y, Tu S-M, Jones RB, Tannir NM, Bassett RL, Margolin DA, Holmberg L, Champlin RE, Pagliaro LC. Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT). J Clin Oncol 32(5s):suppl; abstr 4517, 2014.
34. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin S-H, Logothetis C, Tu S-M. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32:suppl; abstr e16046, 2014.
35. Matrana M, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of unselected patients with metastatic renal cell carcinoma treated with front-line pazopanib therapy. Ann Oncol 24:2779, 10/2013.
36. Yetil A, Jonasch E, Wang X, Wood C, Matin S, Tran HT, Tannir NM, Heymach JV, Zurita AJ. Plasma cytokine and angiogenic factor (CAF) profiling for identification of markers associated with clinical benefit from bevacizumab (BEV) and with primary tumor presence in a phase II presurgical study of metastatic renal cell carcinoma (mRCC) patients. Cancer Res 73(suppl 8) (#4645), 8/2013.
37. Atkinson BJ, Kalra S, Wang X, Bathala T, Perpich J, Corn PG, Tannir NM, Joneasch E. Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single -center experience. J Clin Oncol 31(Suppl) (#e15611), 6/2013.
38. Malouf G, Tannir NM. Integrated transcriptome and methylome sequencing of Xp11 translocation renal cell carcinomas reveal uncoupling of DNA methylation and transcriptional profiles. Amer Assoc for Cancer Res 73(Suppl 8) (#2980), 4/2013.
39. Parker PA, Alba F, Fellman B, Urbauer D, Li Y, Ng C, Karam JA, Tannir NM, Liu XD, Wood C, Matin S. Role of uncertainty on quality of life (QOL) in patients with localized renal tumors on active surveillance (AS): A prospective 2-year study. J Urol 189(4) (#1309), 4/2013.
40. Atkinson BJ, Kalra S, Wang X, Tannir NM, Jonasch E. A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule. J Clin Oncol 31(suppl 6):abstr 381, 2013.
41. Merrill MM, Wood CG, Tannir NM, Slack R, Babaian K, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Characteristics and clinical outcomes of patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). J Clin Oncol 31(suppl 6):abstr 401, 2013.
42. Kenney P, Karam J, Levey R, Nogueras-Gonzalez G, Matin S, Tamboli P, Tannir N, Wood C. Clinical predictors for the development of pulmonary metastases among RCC patients with indeterminate pulmonary nodules. J Urol 189(4) (#1073), 2013.
43. Yennurajalingam S, Reddy AS, Tannir NM, Lee RT, Lopez G, Escalante C, Manzullo EF, frisbee-Hume S, Tarleton K, Williams JL, Palla SL, Cohen L, Bruera E. High dose Asian ginseng, (Panax Ginseng) for cancer related fatigue (CRF): A preliminary report. J Clin Oncol 31(Suppl) (#9642), 2013.
44. Jonasch E, Thakur S, Sircar K, Tamboli P, Tannir NM, Monzon FA. Impact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agents. J Clin Oncol 31(suppl 6):abstr 393, 2013.
45. Cauley DH, Atkinson BJ, Ng CS, Millikan RE, Xiao L, Corn PG, Jonasch E, Tannir NM. mTOR inhibitor-associated noninfectious penumonitis in patients with metastatic renal cell cancer: a single-center experience. J Clin Oncol 31(Suppl) (#e15612), 2013.
46. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn PG, Charnsangavej C, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updates results. J Clin Oncol 31(suppl 6):abstr 367, 2013.
47. Babaian K, Matin SF, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6):abstr 440, 2013.
48. Thompson JA, Forero A, Heath EI, Pal SK, Ansell SM, Infante JR, De Vos S, Hamlin PA, Whiting NC, Zhao B, Tannir NM. SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6):abstr 368, 2013.
49. Conter HJ, Wood CG, Matin SF, Tamboli P, Millikan RE, Jonasch E, Tannir NM. Ten-year follow-up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: Results from a randomized trial. J Clin Oncol 31(suppl 6):abstr 365, 2013.
50. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do K-A, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol 31(suppl 6):abstr 371, 2013.
51. Aparicio A, Sun J, Tang DN, Arap W, Araujo J, Corn, P, Tannir NM, Wang X, Siefker-Radtke A, Sharma P. A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma. Cancer Res 72(suppl 8) (#5368), 6/2012.
52. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Obesity, weight gain, physical activity and polymorphism in mTOR pathway and risk of renal cell carcinoma. Cancer Res 72(suppl 8) (#673), 6/2012.
53. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge K, Dykema K, Petillo D, Teh BT, Tannir NM, Jonasch E, Hung MC. SETD2, a histone methyltransferase, is misregulated in advanced clear cell renal cell carcinoma (ccRCC). Cancer Res 72(suppl 8) (#1035), 6/2012.
54. Cohen L, Tannir NM, Liu XD, Pisters L, Matin S. Spelman A, Wei Q, Wood C. Short- and long-term effects of expressive writing in patients with renal cell carcinoma. BMC Compl and Alt Med 12(1) (#P02.21), 6/2012.
55. Kenny P, Chapin B, Culp S, Richey S, Nogueras-Gonzalez G, Tamboli P, Tannir NM, Wood C. Does cytoreductive nephrectomy improve survival in non-clear cell renal cell carcinoma?. J Urol (#1802), 4/2012.
56. Burnight T, Wood CG, Tannir NM, Jonasch E, Pisters LL, Matin SF, Spelman A, Wei Q, Cohen. A randomized controlled trial of expressive writing for patients with renal cell carcinoma (RCC). J Clin Oncol 30(Suppl):abstr 9029, 2012.
57. Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Bull J, Phan AT, Tannir NM Litton JK, Palmer JL, Reddy AS, Hui D, Dalal S, Massie L, Vadhan-Raj S, Reddy SK, Reuben JM, Bruera E. Dexamethasone (DM) for cancer-related fatigue: A double -blinded, randomized, placebo-controlled trial. J Clin Oncol 30(Suppl):abstr 9002, 2012.
58. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol Suppl 5(abstr 401), 2012.
59. Malouf G, Monzon FA, Couturier J, Molinie V, Escudier BJ, Camparo P, Tamboli P, Wood CG, Tannir NM. Genomic analysis of translocation renal cell carcinoma: Association of frequent 3p loss and poor outcome. J Clin Oncol 30(Suppl 5):abstr 360, 2012.
60. Petillo D, Ho T, Monzon FA, Hoang A, Tampoli P, Furge K, Dykema K, Teh BT, Tannir NM, Hung MC, Liu XD. Identifying SETD2-epigenetically regulated pathways to target kidney cancer metastases. BJU Int 110(suppl 2):17 (#36), 2012.
61. Atkinson B, Kalra S, Wang X, Tannir NM, Jonasch E. Improved outcomes with sunitinib alternative schedule compared to traditional schedule: A single-center retrospective review. BJU Int 110(suppl 2):2 (#05), 2012.
62. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Kydema K, Petillo D, Teh BT, Tannir NM, Hung MC, Jonasch E. Molecular characterization of SETD2, a histone methyltransferase, in clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl):abstr 4624, 2012.
63. Chapin BF, Delacroix SE, Kenney PA, Nogueras Gonzalez GM, Tamboli P, Jonasch E, Tannir NM, Wood CG. Nodal disease in the setting of metastatic renal cell carcinoma: Can a lymph node dissection alter outcomes?. J Clin Oncol 30(Suppl 5):abstr 386, 2012.
64. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. J Clin Oncol 30(Suppl):abstr 4615, 2012.
65. Nieto Y, Tannir NM, Tu S-M, Jones RB, Zurita AJ, Aparicio A, Bassett R, Margolin KA, Holmberg L, Champlin RE, Pagliaro LC. Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT). J Clin Oncol 30(Suppl):abstr 4533, 2012.
66. Haddad H, Rini BI, Jonasch E, Tannir NM, Dreicer R, Garcia JA, Wood LS, Elson P. Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 30(Suppl):abstr4609, 2012.
67. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Dykema K, Petillo D, Teh BT, Tannir NM, Hung M-C, Jonasch E. Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl 5):abstr 368, 2012.
68. Matrana MR, Rao P, Atkinson BJ, Guo C, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experience. J Clin Oncol 30(Suppl 5):abstr 431, 2012.
69. Flaherty A, Matrana MR, Atkinson BJ, Tannir NM. Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series. J Clin Oncol 30(Suppl 5):abstr 453, 2012.
70. Monson FA, Alvarez K, Peterson L, Tannir NM, Jonasch E. Chromosome 14q loss leads to haploinssuficiency of HIF-1a and poor outcomes in metastatic clear cell renal cell carcinoma. Cancer Res 71(suppl 8) (#3491), 7/2011.
71. Chapin BF, Delacroix SE, Culp SH, Nogueras-Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Post-operative complications from cytoreductive nephrectomy after pre-surgical targeted threapy for metastatic renal cell carcinoma. J Urol 185(4) (#1767), 4/2011.
72. Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Kracht K, Sun Y, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29(suppl 7):abstr 309, 2011.
73. Aparicio A, Harzstark AL, Lin E, Corn PG, Araujo JC, Tu S, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Line AM, Small EJ, Mathew P, Jones DM, Troncoso P, Thall PF, Logothetis C, Prostate Cancer Clinical Trials Consortium. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29(Suppl):abstr 4666, 2011.
74. Jonasch E, Alvarez K, Peterson L, Tannir NM, Sircar K, Tamboli P, Monzon FA. Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma. j Clin Oncol 29(suppl 7):abstr 339, 2011.
75. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Wood CG. Early primary tumor response is an independent predictor of overall survival in patients with metastatic RCC undersgoing treatment with sunitinib. J Urol 185(suppl 4) (#1998), 2011.
76. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol 29(suppl 7):abstr 332, 2011.
77. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 29(suppl 7):abstr 346, 2011.
78. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol 29(suppl 7):abstr 351, 2011.
79. Tannir NM, Lim ZD, Rao P, Tamboli P, Atkinson B, Vaishampayan U, Plimack E, Rathmell K, Jonasch E. Outcome of patients with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. J Clin Oncol 29(suppl 7):abstr 386, 2011.
80. Chapin BF, Wood CG, Jonasch E, Tannir N, Tamboli P, Culp SH, Delacroix SE, Gonzalez G. Timing of cytoreductive nephrectomy does not influence survival in metastatic renal cell carcinoma. J Urol 185(suppl 4) (#1759), 2011.
81. Verma J, Jonasch E, Allen P. Tannir NM, Mahajan A. Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review. J Clin Oncol 29(suppl 7):abstr 340, 2011.
82. Mahajan A, Verma JA, Jonasch E, Tannir N, Allen PK. Tyrosine kinase inhibitors and the treatment of brain metastases in metastatic renal cell carcinoma. Amer Radium Soc SS01(CNS Cancer):Abstract ID: 35411, 2011.
83. Abel E, Culp SH, Tannir NM, Matin SF, Tamboli P, Wood CG. Use of early primary tumor response to predict overall survival in patients with metastatic RCC undergoing treatment with sunitinib. J Clin Oncol 29(suppl 7):abstr 329, 2011.
84. Abel EJ, Culp S, Tannir NM, Matin S, Jonasch E, Wood CG. Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma?. J Urol 183(4) (#1661), 4/2010.
85. Margulis V, Matin S, Jonash E, Tamboi P, Tannir NM, Swanson D, Wood C. Impact of delay from diagonsis to cytoreductve nephrectomy on oncologic outcomes of patients with metastatic renal cell carcinoma. J Urol 183(4) (#1657), 4/2010.
86. Karam J, Varella L, Garcia J, Dreicer R, Campbell S, Jonasch E, Tannir NM, Rini B, Wood C. Metastasectomy following targeted therapy in patients with renal cell carcinoma. J Urol 183(4) (#1658), 4/2010.
87. Karam JA, Ahrar K, Jonasch E, Tannir NM, Vikram R, Romero C, Wood CG Matin SF. Radiofrequency ablation (RFA) of renal tumors: Clinical, radiographic, and pathologic results from a tertiary cancer centre. Eur Urol 9(2) (#762), 4/2010.
88. Ilias-Khan NA, Khakoo AY, Tannir NM. A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. J Clin Oncol 28(15s):suppl; abstr 4601, 2010.
89. Wilhelm KL, Atkinson BJ, Khakoo AY, Tannir NM, Jonasch E. A retrospective evaluation of antiangiogenic therapy induced hypertension in metastatic renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15047, 2010.
90. Monzon FA, Alvarez K , Amato RJ, Peterson L, Shen SS, Hernandez-McClain J, Sircar K, Tamboli P, Tannir NM, Jonasch E. Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15012, 2010.
91. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 28(15s):suppl; abstr 4613, 2010.
92. Tannir NM, Wong Y, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, E. M. Posadas, Qian J, Ricker JL, Michaelson D. Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. J Clin Oncol 28(15s):4527, 2010.
93. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol 28:suppl; abstr e15083, 2010.
94. Atkinson BJ, Perpich J, Tannir NM, Jonasch E. Schedule modifications and treatment outcomes for sunitinib-related adverse events. J Clin Oncol 28:suppl; abstr e15115, 2010.
95. Plimack ER, Jonasch E, Bekele BN, Qiao W, Ng CS, Tannir NM. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. J Clin Oncol 28(15s):suppl; abstr 4604, 2010.
96. Matin SF, McCutcheon IE, Gombos DS, S. Waguespack, N. M. Tannir, Wen S, Davis DW, Smith LA, Fuller G, Jonasch E. Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies. J Clin Oncol 28(15s):3040, 2010.
97. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol 28(15s):suppl; abstr 4606, 2010.
98. Tannir NM, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM. Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure. EJC Suppl 7(2) (#7109), 9/2009.
99. Culp SH, Abel EJ, Margulis V, Bill KL, Tampoli P, Jonasch E, Matin SF, Swanson DA, Tannir NM, Wood CG. Identifying patients with metastatic renal cell carcinoma who will not benefit from cytoreductive nephrectomy. J Urol 181(suppl 4):498 (#1394), 4/2009.
100. Heymach J, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15s):spllu; abstr 5114, 2009.
101. Siefker-Radtke AO, Kamat AM, Williams DL, Tannir NM, Tu S. Pagliaro LC, Dinney C, Millikan RE. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 27(15s):suppl; abstr 5071, 2009.
102. Montero AJ, Diaz-Montero CM, Liu J, Do K, Millikan RE, Tannir NM. Cytokines and angiogenic factors in metastatic renal cell cancer: Association of pre-treatment serum levels with survival. J Clin Oncol 27:suppl; abstr e16036, 2009.
103. Falchook GS, Wheler JJ, Tannir NM, Maing A, Jackson EF, Hong D, Lawhorn KN, Ng CS, Amin H, Kurzrock R. Hypoxia-inducible factor 1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol 27(15s):suppl; abstr 3555, 2009.
104. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN). J Clin Oncol 27:suppl; abstr e16035, 2009.
105. Atkinson B, Hart J, Lin E, Tannir N, Jonasch E. Patient characteristics associated with dose-limiting sunitinib adverse events. J Clin Oncol 27:suppl; abstr e16110, 2009.
106. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(15s):suppl; abstr 5004, 2009.
107. Tannir N, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. J Clin Oncol 27(15s):suppl; abstr 5036, 2009.
108. Johnson ED, Tannir NM, Olejeme KA, Logothetis CJ, Jonasch E. Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol 27:suppl; abstr e16096, 2009.
109. Miller L, Lal LS, Tannir NM, DaCosta Byfield S, Atkinson B, Feng C, Lau JK, Yin L, Jonasch E. Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. J Clin Oncol 27:suppl; abstr e16112, 2009.
110. Shao L, Lin J, Matin S, Tannir NM, Wood CG Wu X. FAmilial risk of kidney cancer. Ann Epidemiology 18(9) (#P23), 9/2008.
111. Pagliaro LC, Tannir NM, Tu S, Moomey B, Carter CM, Bekele N, Mathew P. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy. J Clin Oncol 26:13545, May 20 suppl, 2008.
112. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro L, Corn P, Aparicio A, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26:5093, May 20 suppl, 2008.
113. Falchook GS, Jackson EF, Wheler JJ, Moulder SL, Hong DS, Naing A, Tannir NM, Lawhorn KN, Ng CS, Kurzrock R. Anti-angiogenic therapy in combination with hyposix-inducible factor-1α (HIF-1α) modulation. J Clin Oncol 26:14604, May 20 suppl, 2008.
114. Dubauskas Z, Kunishige J, Prieto VG, Hwu P, Jonasch E, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: A single institution experience. J Clin Oncol 26:16101, May 20 suppl, 2008.
115. Araujo JC, Jonasch E, Tannir NM, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26:5106, May 20 suppl, 2008.
116. Jonasch E, Wood CG, Matin S, Tamboli P, Do K. Pagliaro LC, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26:5104, May 20 suppl, 2008.
117. Tsavachidou D, Tannir NM, Thomas C, Mills GB, Jonasch E. Reverse-phase protein array marker evaluation of protein expression patterns related to anti-angiogenesis treatment in renal cell carcinoma. J Clin Oncol 26:16016, May 20 suppl, 2008.
118. Mathew P, Pagliaro LC, Tannir NM, Tu S, Marcott V, Patterson L, Reed K, Bekele N, Logothetis CJ. Single-agent platelet-derived growth factor (PDGF) receptor inhibitor therapy for castration-resistant prostate cancer with bone metastases. J Clin Oncol 26:5164, May 20 suppl, 2008.
119. Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study. J Clin Oncol 26:5112, May 20 suppl, 2008.
120. Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A, Thiele A, Strahs A, Feingold J. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients for advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25(18S):Abstract 5033, June 20 Supplement, 2007.
121. Matin S, Tannir N. Laparoscopic salvage nephrectomy after targeted neoadjuvant therapy for metastatic renal cell carcinoma: Initial results. J Clin Oncol 25(Moderated Poster Acceptance):Abstract 97323, 2007.
122. Camacho LH, Hong DS, Gutierrez C, Parker CA, Purdom MA, Tannir NM, Moulder S, Gale RP, Schwartz B, Kurzrock R. Organic arsenic in patients (pts) with advanced solid tumors: Phase 1 results of Z10-101 (s-dimethylarsino-glutathione). J Clin Oncol 25(18S):Abstract 3554, June 20 Supplement, 2007.
123. Hong DS, Camacho L, Ng C, Wright J, Newman RA, Moulder S, Tannir N, Wheler J, Khan R, Kuzrock R. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers (NCI protocol 7156 supported by NCI grant U01 CA062461). J Clin Oncol 25(18S):Abstract 3549, June 20 Supplement, 2007.
124. Jonasch E, Corn P, Ashe RG, Do D, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 25(18S):Abstract 5104, June 20 Supplement, 2007.
125. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S, Jonasch E. Von Hippel-Lindau gene mutation status is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. J Clin Oncol 25(18S):Abstract 15522, 2007.
126. Jonasch E, TsavachidouD, Wood C, Tamboli P, Tu S, Thomas C, Do KA, Matin S, McDonnell T, Tannir NM. Presurgical treatment of metastatic renal cell carcinoma patients with bevacizumab and erlotinib: preliminary efficacy and biomaker data. EJC Suppl 4(12):80 (#250), 11/2006.
127. Camacho LH, Hong DS, Gutierrez C, Vertovsek S, Tannir N, Parker CA, Purdom MA, Lewis J, Gale RP, Kurzrock R. Phase 1 trial of Z10-101, a novel organic arsenic in patients with advanced cancers. J Clin Oncol 24:Abstract 13041, 2006.
128. Montero AJ, Diaz-Montero C, Wang X, McIntyre BW, Tannir N. Predictive utility of serum cytokine levels in patients with metastatic renal cell carcinoma (MRCC) treated with interferon alfa (IFNa). J Clin Oncol 24:Abstract 14503, 2006.
129. Spiess PE, Brown GA, Liu P, Tannir NM, Tu S, Kamat AM, Pisters LL. Predictors of survival in patients undergoing post-chemotherapy retroperitoneal lymph node dissection. J Clin Oncol 24(18S):Abstract 4593, 2006.
130. Lina S, Wood CG, Zhang D, Tannir NM, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a predisposition factor for renal cancer. Proc Amer Assoc Cancer Res 26:4990, 2006.
131. Rodney AJ, Siefker-Radtke A, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M.D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 24(18S):Abstract 14538, 2006.
132. Tannir NM, Jonasch E, McMichael C, Wang X, Wooten L, Ng CS. A phase II trial of gemcitabine plus capecitabine (GX) in patients with advanced renal cell cancer (mrcc) previously treated with immunotherapy. J Clin Oncol 23(16S):Abstract 4598, 2005.
133. Ebinghaus SW, Hussain M, Tannir NM, Gordon MS, Desai AA, Knight RA, Carlson DM, Giflin RA. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. J Clin Oncol 23(16S):Abstract 4607, 2005.
134. Jonasch E, Tu S-M, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke AO, Wen S, General R, Lin S-H, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma: A phase II study. J Clin Oncol 23(16S):Abstract 4769, 2005.
135. Rodney AJ, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer with prior taxane exposure. J Clin Oncol 23:Abstract 4750, 2005.
136. Tannir NM, Cohen L, Wang X, Ng CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Millikan RE. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as frontline therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 22(14S):Abstract 4607, 2004.
137. Siefker-Radtke AO, Thall PF, Tannir NM, Tu SM, Pagliaro, LC, Williams DL, Millikan, RE. Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M D Anderson Cancer Center. J Clin Oncol 22(14S):Abstract 4543, 2004.
138. Daliani D, Dieringer P, Matthew P, Pagliaro L, Davies K, Tannir NM, Chen I, Jonasch E, Papandreou C, Logothetis C. A tolerance and efficacy study of thalidomide, paclitaxel, estramustine combination for patients with chemotherapy refractory androgen independent prostate carcinoma. EJC Suppl 1(5):s261 (#868), 9/2003.
139. Ueno NT, Cheng YT, Giralt SA, RondÓn G, Gajewski JL, Tannir NM, Pagliaro LC, Hortobagyi GN, Champlin RE. Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic renal cell carcinoma (RCC) and breast cancer (BC). J Clin Oncol 20:Abstract #1659, 2002.

Grant & Contract Support

Title: Molecular genetic and epigenetic characterization of translocation renal-cell carcinoma (RCC): Comparison of pediatric and adult forms
Funding Source: Kidney Cancer Research Group
Role: Principal Investigator
Duration: 2/1/2012 - 1/30/2013
 
Title: Molecular genetic and epigenetic characterization of translocation renal-cell carcinoma (RCC): Comparison of pediatric and adult forms
Funding Source: Kidney Cancer Research Group
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2011

Last updated: 7/18/2016